First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

Authors

Tony Mok

The Chinese University of Hong Kong, Hong Kong, China

Tony Mok , Dong-Wan Kim , Yi-Long Wu , Benjamin J. Solomon , Kazuhiko Nakagawa , Tarek Mekhail , Enriqueta Felip , Federico Cappuzzo , Jolanda Paolini , Tiziana Usari , Jennifer Tursi , Fiona Helen Blackhall

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

First Author: Myung-Ju Ahn

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

First Author: Shun Lu

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

First Author: Helena Alexandra Yu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

First Author: Martin Reck